Working… Menu

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02315703
Recruitment Status : Active, not recruiting
First Posted : December 12, 2014
Last Update Posted : June 17, 2019
National Institute of Allergy and Infectious Diseases (NIAID)
US Military HIV Research Program
Beth Israel Deaconess Medical Center
International AIDS Vaccine Initiative
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.